Business Wire

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence

Jaa

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US.

Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb. He currently serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics and Viking Therapeutics, with previous board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. He holds an M.B.A. from Rutgers University and a B.S. from Saint Joseph's University.

Duncan Higgons has most recently served as a member of the board of directors of Jounce Therapeutics since November 2015. He served as COO of Agios Therapeutics, Inc. from 2009 to 2016 where he was responsible for leading a transformative deal with Celgene and for building the company including a successful IPO. Before joining Agios he served as Executive Vice-President, and Interim President and CEO at Archemix Corporation from 2006 to 2009 and prior to that he served as the Chief Commercial Officer (CCO) at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Earlier in his career, he held roles of increasing seniority in strategic planning, marketing, sales and business development at Eli Lilly, Baxter and Alkermes, becoming Senior Vice President, Business Operations and Marketing at Alkermes where he negotiated numerous partnership and licensing deals. Duncan holds a B.Sc. in Mathematics from King’s College University of London and an M.Sc. in Economics from London Business School.

“I am delighted to welcome both Charlie and Duncan to strengthen the PsiOxus Board at this key stage of our growth,” stated Paolo Paoletti, Chairman of the PsiOxus Board of Directors “these two US based Board appointments are critical as PsiOxus continues to mature and internationalise”.

“Together with the recent opening of our facility near Philadelphia, the addition of two US based Board Directors is a continuation of our commitment to become an international biotech and a leader in oncolytic immunotherapy” added John Beadle, Chief Executive Officer. PsiOxus completed two deals with Bristol-Myers Squib (BMS) in 2017 including a transformative pre-clinical deal on NG-348, an innovative gene therapy product for cancer based upon the company’s Tumor-Specific Immuno-Gene therapy (T-SIGn) platform.

About PsiOxus Therapeutics Ltd.

PsiOxus Therapeutics is a development stage biotechnology company focused upon immune-oncology with headquarters near Oxford, UK and offices near Philadelphia, USA. PsiOxus has developed the proprietary Tumor-Specific Immuno-Gene therapy (T-SIGn) platform for systemic delivery of tumor-targeted oncolytic immune therapeutics. The T-SIGn platform is based on the company's oncolytic virus, enadenotucirev, which can be delivered by intravenous administration and replicates only in tumor cells. Enadenotucirev is currently in a clinical trial under a US IND in combination with nivolumab (Opdivo ®) in collaboration with Bristol-Myers Squib (BMS). The anticancer capability of the T-SIGn platform is further enhanced through “arming” the virus with transgenes. The armed T-SIGn platform makes possible creation of a broad range of systemically delivered oncolytic immune therapeutics including oncolytic viruses that express one or more antibodies, cytokines, immunomodulatory proteins, or nucleotide (RNA) based payloads. T-SIGn thus opens up the possibility of gene therapy for cancer. NG-348, the first T-SIGn product was licensed to BMS in 2017 with an upfront payment of $50million.

View this news release online at: www.psioxus.com

Contact information

PsiOxus Therapeutics Ltd.
John Beadle, +44 1235 42 98 40
john.beadle@psioxus.com
or
For investors:
Burns McClellan, Inc., on behalf of PsiOxus
Therapeutics Ltd.
Ben Matone, 2122130006
bmatone@burnsmc.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares19.2.2018 21:19Tiedote

Zonoville Investments Limited, a consortium of investors led by Renova Group and Access Industries, announced today that it had reached an agreement with Onexim Group to purchase its 6% stake in the United Company RUSAL Plc. Following completion of the purchase, Zonoville Investments Limited and its associate SUAL Partners Limited will hold, in aggregate, approximately a 26.5% interest in United Company RUSAL Plc. About Renova Renova Group of companies (www.renova.ru) is a major private Russian business group which owns and manages assets in metallurgy, mining, chemical, construction, transport, energy, telecommunications, high-tech engineering, public utilities, medicine and financial sectors in Russia and abroad (CIS, Switzerland, Italy, South Africa and the United States of America). Renova’s largest assets include its interests in UC Rusal, T Plus Group, OCTO Telematics and Swiss-based technology concerns Schmolz+Bickenbach, OC Oerlikon, and Sulzer. About Access Industries Founded

The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London19.2.2018 21:05Tiedote

Medical innovation will take centre stage for 2018, at the largest wearables and disruptive health technology event in the world, with never before-seen devices and applications and a raft of industry-leading speakers. The Digital Health Technology Show returns to London on the 13th & 14th March 2018 at London’s Excel, gathering together more than 6,000 attendees and over 100 exhibitors. The 2018 Conference programme boasts three tracks, with over 100 hours of content programmed. Attendees can choose to attend talks on the Digital Health Disrupt Stage – covering global innovation in healthcare, the Leadership Theatre – where senior healthcare figures in the UK will discuss and debate the challenges ahead, or the Patient Engagement Stage – delivering insights into how technology is being used in the real world. There will also be demonstrations of the latest medical innovations on the Innovation Stage, which will also host a start up competition – The Health Innovation Award. Over 200 s

World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London19.2.2018 16:00Tiedote

The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/ Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire) The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based pro

Tampere Attracts AV Productions with a New Incentive19.2.2018 15:41Tiedote

One of the City of Tampere’s strategic goals is to be an international meeting place for creativity and innovation. The development of the experience economy is an essential focus of the city’s business policy. The incentive system is being used to attract more local, national and international productions to the Tampere region. The goal is to promote the development of the industry and to increase the number of jobs and the turnover of commercial productions in Tampere. Through the incentive system, an audiovisual production may recover some of the costs it has spent on wages and service purchases in the Tampere region. A production meeting the incentive criteria may be refunded 10–15 per cent of the accepted costs accrued in the region. Professional productions that utilise the Tampere region as their location or use expertise from the area may apply for the incentive. Thanks to the growing number of productions, Tampere will become more visible in films and TV shows, which will add

Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 14:14Tiedote

Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an

Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 13:05Tiedote

Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme